Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company

Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline

Fineline Cube Apr 29, 2025

China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing...

Company Deals

OUR United Corporation Files for IPO in Hong Kong Stock Exchange

Fineline Cube Apr 29, 2025

China-based OUR United Corporation, a leading provider of radiosurgical solutions, has filed for an initial...

Company Drug

Henlius Biotech’s HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers

Fineline Cube Apr 29, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received clinical trial approval...

Company Deals

GenScript to Acquire Additional Stake in Probio Cayman for USD 225.1 Million

Fineline Cube Apr 29, 2025

GenScript Biotech Corporation (HKG: 1548) is set to acquire an additional 300 million Class A...

Company

CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact

Fineline Cube Apr 29, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8%...

Company

Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report

Fineline Cube Apr 29, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) released its 2024 financial report, highlighting a robust growth...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma

Fineline Cube Apr 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Company Drug

Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors

Fineline Cube Apr 28, 2025

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...

Company Deals

Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility

Fineline Cube Apr 28, 2025

Shanghai-listed biopharmaceutical company Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) has announced plans to invest...

Company Drug

Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers

Fineline Cube Apr 28, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company

Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply

Fineline Cube Apr 28, 2025

German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)...

Company Drug

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

Fineline Cube Apr 28, 2025

Zhejiang-based Zhejiang Shimai Pharmaceutical Co.,Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...

Company Drug

Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy

Fineline Cube Apr 28, 2025

US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...

Company Drug

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors

Fineline Cube Apr 28, 2025

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...

Company Medical Device

Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China

Fineline Cube Apr 28, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...

Company Medical Device

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Apr 28, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has secured marketing approval...

Others

Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics

Fineline Cube Apr 28, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported Q1 2025 financials with global group...

Company

BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline

Fineline Cube Apr 28, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...

Company

Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China

Fineline Cube Apr 27, 2025

Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors

Fineline Cube Apr 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...

Posts pagination

1 … 223 224 225 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.